 |
1. The 49th Interscience Conference |
|
|
2. DHHS and IAS-USA: Recommendations for Initiation of ART in Naive Patients |
|
|
3. Time to CD4+ Count <= 500 |
|
|
4. Tropism Status and Risk of Disease Progression |
|
|
5. CIPRAHT001: Randomized Trial |
|
|
6. CIPRAHT001: Clinical Endpoints |
|
|
7. DHHS Guidelines |
|
|
8. ARTEN: Comparison of Nevirapine QD or BID |
|
|
9. ARTEN: Baseline Characteristics |
|
|
10. ARTEN: Results at Week 48 |
|
|
11. ARTEN: Early Virologic and Immunologic Responses |
|
|
12. MERIT ES: Comparison of Efavirenz |
|
|
13. MERIT-ES: Virologic Response |
|
|
14. MERIT: Inflammatory Marker Substudy |
|
|
15. What Happens To Those Who Opt-out of HIV Testing |
|
|
16. HIV Testing with STD Diagnoses |
|
|
17. HIV Testing with STD Diagnoses |
|
|
18. STARTMRK: Raltegravir vs. Efavirenz |
|
|
19. STARTMRK: Baseline Characteristics |
|
|
20. STARTMRK: Virologic Efficacy |
|
|
21. STARTMRK: Adverse Events |
|
|
22. Raltegravir + Atazanavir |
|
|
23. Pilot Study of Raltegravir QD vs. BID |
|
|
24. Efficacy and Safety of Raltegravir |
|
|
25. STARTMRK: Resistance Mutations |
|
|
26. STARTMRK: Resistance Mutations 2 |
|
|
27. Achieving Virologic Suppression |
|
|
28. Reestablishing Suppression |
|
|
29. VICTOR-E1 |
|
|
30. Victor-E1: Results of 48-Week Extension |
|
|
31. PRO 140: Phase II Data |
|
|
32. Beviramat: Study 204 Phase II Data |
|
|
33. S/GSK1349572: The 3rd Integrase Inhibitor? |
|
|
34. S/GSK1349572: Antiviral Activity |
|
|
35. S/GSK1265744: Phase I Program |
|
|
36. S/GSK1265744: Antiviral Activity |
|
|
37. S/GSK1265744 |
|
|
38. S/GSK1265744: Safety and Resistance |
|
|
39. MERIT: Comparison of Lipid Changes |
|
|
40. MERIT: More Patients on EFV than MVC Exceed |
|
|
41. STARTMRK: Mean Changes in Metabolic Parameters |
|
|
42. STARTMRK: Mean Change in Metabolic Parameters 2 |
|
|
43. STARTMRK: Mean Change in DEXA Morphological Parameters to Week 48 |
|
|
44. GS 934 Extension: Study Design |
|
|
45. GS 934 Extension: Virologic Results |
|
|
46. GS 934 Extension: Median Estimated GFR |
|
|
47. GS934 Extension: Median Change in Fasting Lipids After Switch to EFV/TDF/FTC |
|
|
48. GS 934 Extension: Median Change in Total Limb Fat After Switch to EFV/TDF/FTC |
|
|
49. Metabolic Impact of Switch to Raltegravir 400mg BID + Atazanavir 400mg QD |
|
|
50. Impact of ART on Flow Mediated Dilatation |
|
|
51. CDC Initiatives in HIV Testing |
|
|
52. Changes in Pulmonary Function |
|
|
53. B-Glucan as Predictor of Pneumocystis jirovecii Pneumonia |
|
|
54. Causes of Bacterial Pneumonia |
|
|
55. When and How to Treat MDR-TB |
|
|
56. Early vs Deferred ART for TB Meningitis |
|
|
57. Early Antiretroviral Therapy Does Not Improve Mortality in TB Meningitis |
|
|
58. Darunavir and Raltegravir Achieve Suppressive Levels in CSF |
|
|
59. INSPIRE: |
|
|
60. BITE Study: Nutritional Supplement Slows CD4+ T Cell Declines |
|
|
61. Treatment for Acute HCV Infection in HIV Co-infected Patients |
|
|
62. 24-hour HCV Viral Decay |
|
|
63. Risk Factors Associated with Non-response to HBV Vaccination |
|
|
64. DRV Pharmacokinetic Studies |
|
|
65. Raltegravir – Drug Interaction Studies |
|
|
66. PK and Safety of Boosting Atazanavir with GS-9350 vs. Ritonavir |
|
|
67. Effect of Food on PK |
|
|
68. PK of NVP Extended Release vs Immediate Release |
|
|
69. HPV Related Cancers |
|
|
70. HPV Related Cancers |
|
|
71. Algorithm for Anal Cytology |
|
|
72. TDF in Pregnancy |
|
